Kalaris Therapeutics (KLRS) Income from Continuing Operations (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Income from Continuing Operations of 16519000.0 for Q1 2026, up 69.98% year-over-year from 9718471.96 in Q1 2025, and down 52.94% quarter-over-quarter from 10801000.0 in Q4 2025.
Kalaris Therapeutics (KLRS) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 16519000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 69.98% year-over-year to 16519000.0; the TTM figure through Mar 2026 stood at 60313000.0 (up 43.53% YoY), while the FY2025 annual figure was 55698000.0, up 9.77% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 16519000.0, down from 10801000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 2739000.0 in Q1 2024, with the low at 205415000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 38664000.0 (2024), against an average of 37852000.0.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations plunged 7034.94% in 2023, then surged 95.89% in 2024.
- Kalaris Therapeutics' Income from Continuing Operations stood at 2879000.0 in 2022, then slumped by 7034.94% to 205415000.0 in 2023, then soared by 95.89% to 8442000.0 in 2024, then slipped by 27.94% to 10801000.0 in 2025, then plunged by 52.94% to 16519000.0 in 2026.
- Business Quant data shows KLRS's Income from Continuing Operations at 16519000.0 in Q1 2026, 10801000.0 in Q4 2025, and 18609000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | -12.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.08 Mn |
| Mar 31, 2026 | -16.52 Mn |
| Dec 31, 2025 | -10.80 Mn |
| Sep 30, 2025 | -18.61 Mn |
| Jun 30, 2025 | -14.38 Mn |
| Mar 31, 2025 | -55.02 Mn |
| Dec 31, 2024 | -8.44 Mn |
| Sep 30, 2024 | -38.66 Mn |
| Jun 30, 2024 | -4.69 Mn |
| Mar 31, 2024 | -2.74 Mn |
| Dec 31, 2023 | -205.42 Mn |
| Sep 30, 2023 | -44.27 Mn |
| Jun 30, 2023 | -45.27 Mn |
| Mar 31, 2023 | -45.16 Mn |
| Dec 31, 2022 | -2.88 Mn |
| Sep 30, 2022 | -42.07 Mn |
| Jun 30, 2022 | -44.69 Mn |
| Mar 31, 2022 | -43.86 Mn |
| Dec 31, 2021 | 162.07 Mn |
| Sep 30, 2021 | -45.51 Mn |